Barclays PLC Grows Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC increased its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,013 shares of the company’s stock after buying an additional 12,924 shares during the quarter. Barclays PLC’s holdings in Pyxis Oncology were worth $121,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after purchasing an additional 10,000 shares during the period. American Century Companies Inc. lifted its position in Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock worth $468,000 after buying an additional 140,498 shares in the last quarter. Sei Investments Co. acquired a new position in shares of Pyxis Oncology during the 4th quarter valued at about $95,000. Aristides Capital LLC acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $193,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock valued at $458,000 after purchasing an additional 133,018 shares during the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $1.07 on Thursday. The stock has a market cap of $66.28 million, a PE ratio of -1.04 and a beta of 1.15. Pyxis Oncology, Inc. has a 1 year low of $0.83 and a 1 year high of $5.39. The stock has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.68.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. As a group, equities research analysts predict that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on PYXS shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a research report on Wednesday, March 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.